Clinical Trial Update: Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating enzastaurin for arterial event prevention in vascular Ehlers-Danlos syndrome is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Ehlers-danlos Syndrome

Drugs mentioned

• Enzastaurin (enzastaurin)

Snippet

Sponsor: Aytu BioPharma, Inc. | Conditions: Vascular Ehlers-Danlos Syndrome | Phase 3 | Status: SUSPENDED